A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola

The European Medicines Agency (EMA). Interim assessment report. Review under Article 5(3) of Regulation (EC) no 726/2004. London: EMA, http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179062.pdf (2015, accessed 29 October 2015).

Krause PR Cavaleri M Coleman G . Approaches to demonstration of Ebola virus vaccine efficacy. Lancet Infect Dis 2015; 6: 627–629.

Commission Regulation (EC) 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council. Official Journal of the European Union, http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_507/reg_2006_507_en.pdf (2006, accessed 29 October 2015).

The European Medicines Agency (EMA). Committee for medicinal products for human use. Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to article 14(8) of regulation (EC) no 726/2004. London: EMA, http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004883.pdf (2005, accessed 29 October 2015).

Council Regulation (EC) 726/2004 of 30 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency [2004] OJ L136/1, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF (2004, accessed 29 October 2015).

US Department of Health and Human Services, Food and Drug Administration (FDA). Product development under the animal rule – guidance for industry, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf (2015, accessed 29 October 2015).

World Health Organization (WHO). Ethical issues related to study design for trials on therapeutics for Ebola virus disease. In: WHO ethics working group meeting, 20–21 October 2014 (Summary of Discussion). Geneva: WHO, 2014, http://apps.who.int/iris/bitstream/10665/137509/1/WHO_HIS_KER_GHE_14.2_eng.pdf (2014, accessed 29 October 2015).

Cox E Borio L Temple R. Evaluating Ebola therapies–the case for RCTs. N Engl J Med 2014; 371: 2350–2351.

Adebamowo C Bah-Sow O Binka F . Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014; 384: 1423–1424.

Borio L Cox E Lurie N. Combating emerging threats – accelerating the availability of medical therapies. N Engl J Med 2015; 373: 993–995.

Cooper BS Boni MF Pan-ngum W . Evaluating clinical trial designs for investigational treatments of Ebola virus disease. PLoS Med 2015; 12: e1001815.

Zhang X Rong Y Sun L . Prognostic analysis of patients with Ebola virus disease. PLoS Negl Trop Dis 2015; 9: e0004113.

Fitzpatrick G Vogt F Moi Gbabai O . The contribution of Ebola Viral Load at admisssion and other patient characteristics to mortality in a Médecins Sans Frontières Ebola case management centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis 2015; 212(11): 1752–1758.